AMA releases updated naloxone guidance document

The American Medical Association (AMA) Opioid Task Force has released an updated naloxone guidance document for physicians and other health professionals to “encourage them to co-prescribe naloxone when clinically appropriate.” 

AMA says, “The updated resource recommends that physicians consider several key questions that the task force believes can be helpful when determining whether to co-prescribe naloxone to a patient or to a family member or close friend of the patient, including: Is the patient receiving a high dose of opioids?; Does the patient also have a prescription for a benzodiazepine?; Does the patient have a history of substance use disorder?; Does the patient have an underlying mental health or other medical condition that makes him or her more susceptible to overdose?; and, Would the patient be in a position to help another person at risk of overdose?”

The task force chair, Patrice Harris, M.D., emphasizes that, “If it were not for naloxone, it is likely that many thousands more would be dead from an opioid-related overdose. We know that naloxone – by itself – will not reverse the nation's opioid epidemic, but it is a critical component that saves lives and provides a second chance.”

And AMA explains that, “The updated guidance document, as well as the AMA opioid microsite, also includes links to multiple resources for physicians to use in their practice – ranging from recommendations for use in different settings, best practices and product comparisons.”

Click for updated naloxone guidance document

Click for ‘AMA Opioid Microsite’